Lexicon

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 3, 2024
Webcast, Lexicon

THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm.

Key Points: 
  • THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm.
  • A simultaneous webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events , and a recording of the webcast will be available for two weeks following the original on-demand date.

Lexicon Tech Solutions Welcomes New VP of Channel Development

Retrieved on: 
Wednesday, April 3, 2024
Growth, Knowledge, MMS, Acquisition, IBM, Lexicon, Federal, Professional services, SF, Managed Mobility Services, Solution architecture, CDW, ADP, Management

CONYERS, Ga., April 3, 2024 /PRNewswire/ -- Lexicon Tech Solutions, a leading provider of innovative technology solutions, is pleased to announce the appointment of Jenny Taylor as the new Vice President of Channel Development.

Key Points: 
  • CONYERS, Ga., April 3, 2024 /PRNewswire/ -- Lexicon Tech Solutions, a leading provider of innovative technology solutions, is pleased to announce the appointment of Jenny Taylor as the new Vice President of Channel Development.
  • Throughout her distinguished career, Taylor has held various leadership positions spanning Operations, Global Services, Solution Architecture, Program Management, Sales, Federal, and Channel Management.
  • As the VP of Channel Development at Lexicon, Taylor will focus on developing go-to-market strategies, implementing best practices, and strengthening key partnerships to explore and open new partner sales channels.
  • Lexicon Tech Solutions is thrilled to welcome Jenny Taylor to the team and looks forward to the continued growth and success that her expertise will bring to the organization.

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Retrieved on: 
Monday, March 11, 2024
Chronic kidney disease, Lexicon, CRL, New Drug Application, FDA, CKD, Diabetes, Patient, Hearing, NDA, Pharmaceutical industry

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD). The resubmission is planned for mid-year, with an anticipated six-month regulatory review period.

Key Points: 
  • THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD).
  • The resubmission is planned for mid-year, with an anticipated six-month regulatory review period.
  • “We have remained steadfast in our support of sotagliflozin in type 1 diabetes and have worked diligently to identify a regulatory path forward for what we believe will be an important new therapy,” said Lonnel Coats, Director and Chief Executive Officer.
  • Lexicon and FDA subsequently agreed in late 2023 to hold the NOOH proceedings in abeyance in order to engage in discussions regarding a path forward for resubmission and potential approval of the NDA.

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Research, New Drug Application, American Heart Association, Investment, Obesity, Growth, EASD, Arrowhead Conference, Patient, Chronic kidney disease, Post hoc, Neuropathic pain, Marketing, Heart failure, Hypertension, Hypertrophic cardiomyopathy, Left ventricular hypertrophy, NDA, Express, PROGRESS, AAK1, Risk, Conference, HCM, Clinical trial, Neuroscience, Lexicon, FDA, Research and development, Cardiology, U.S. FDA, Medicare, Administration, Travel, Pharmaceutical industry

ET

Key Points: 
  • ET
    THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones.
  • “2023 was a pivotal year for Lexicon,” said Lonnel Coats, Lexicon’s chief executive officer.
  • Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2023 compared to the fourth quarter and full year of 2022.
  • Revenues: Revenues for the fourth quarter and full year of 2023 were $0.7 million and $1.2 million, respectively, primarily from the commercialization of INPEFA.

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

Retrieved on: 
Thursday, December 21, 2023
Webcast, Conference, Lexicon

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024.
  • Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation at 10:30am PT / 1:30 pm ET on Thursday, January 11th.
  • Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will also participate in the presentation.
  • A simultaneous webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events , and a recording of the webcast will be available for two weeks following the original on-demand date.

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Wednesday, November 22, 2023
Evercore, Webcast, Conference, Lexicon

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023:

Key Points: 
  • THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023:
    Lonnel Coats, Lexicon’s chief executive officer, Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in moderated discussions at the Evercore ISI conference on Tuesday, November 28th, at 2:35 pm ET and at the Piper Sandler Conference on Thursday, November 30th, at 9:30am ET.
  • A simultaneous webcast of both discussions will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events , and a recording of the webcast will be available for two weeks following the original on-demand date.

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Friday, November 10, 2023
Webcast, EST, Lexicon, Conference, GMT

THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023.

Key Points: 
  • THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023.
  • Jeff Wade, Lexicon’s president and chief financial officer, and Tom Garner, Lexicon’s senior vice president and chief commercial officer, will make a company presentation at 5:00 pm GMT / 12:00 pm EST on Wednesday, November 15th.
  • A simultaneous webcast of the presentation will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events , and a recording of the webcast will be available for two weeks following the original on-demand date.

33Across Announces Promotion of Lisa Mollura to Chief Marketing Officer

Retrieved on: 
Tuesday, November 14, 2023
Marketing, Growth, Cookie, Community strategy, Zurich Insurance Group, Rakuten Advertising, Lexicon, Advertising, CMO

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- 33Across, an addressable infrastructure designed for the open web, today announces Lisa Mollura's promotion from Vice President of Marketing to Chief Marketing Officer (CMO). With nearly a decade of commitment to the company, Mollura has played an integral role in the company's transformation, guiding the marketing and communications efforts for the company from a programmatic platform to a leading addressable infrastructure, propelled by the innovative identity solution, Lexicon.

Key Points: 
  • A Decade-Long Dedication to 33Across, Mollura Drives 33Across' Marketing and Communications Strategy
    NEW YORK, Nov. 14, 2023 /PRNewswire/ -- 33Across , an addressable infrastructure designed for the open web, today announces Lisa Mollura's promotion from Vice President of Marketing to Chief Marketing Officer (CMO).
  • "In the past ten years, Lisa has held and led every position in marketing at 33Across, excelling at every opportunity to improve our customer relations and corporate brand.
  • Given 33Across' impressive growth, Mollura's proficiency in diverse marketing strategies plays an important role in the company's plan for further expansion.
  • Prior to 33Across, Mollura held noteworthy roles at Rakuten Advertising and Zurich North America .

33Across' Lexicon Identity Solution Demonstrates Ongoing Publisher Monetization Value with 54 Billion Enriched Bid Requests Daily, Marking a 42% Quarterly Surge

Retrieved on: 
Tuesday, November 7, 2023
Lexicon, DSPS, SSPS, Advertising, Addressability, ID, Ecosystem, Online shopping, Pubmatic

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- 33Across, an addressable infrastructure designed for the open web, today announced that its identity resolution technology, Lexicon, enriches over 54 billion bid requests daily and is currently growing at a 42% rate every quarter. This exponential growth translates to a 10X increase in addressable scale integrated across 5 of the top 7 supply-side platforms (SSPs) and 20 demand-side platforms (DSPs).

Key Points: 
  • This exponential growth translates to a 10X increase in addressable scale integrated across 5 of the top 7 supply-side platforms (SSPs) and 20 demand-side platforms (DSPs).
  • While several identity solutions exist today, many lack scale or meaningful adoption, resulting in a fragmented programmatic ecosystem.
  • Lexicon's integration throughout the ecosystem and data expertise serves as a robust identity solution, resolving to the buyer's chosen ID for improved scalability, greater precision in targeting, and measurement.
  • "Lexicon is an important part of our sell-side targeting offering that helps publishers find new monetization opportunities while enhancing value for advertisers and consumers across the open internet."

Lexicon Strengthens Management Team With Two New Executives

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, National Investor Relations Institute, Professional corporation, Bristol Myers Squibb, Melinta Therapeutics, Policy, AbbVie, Lexicon, Therapy, Ophthalmology, Actavis, Intercept, BS, Seton Hall University, Ozanimod, University, Amarin, Warner Chilcott, MBA, Ladenburg Thalmann, Alemtuzumab, Allergan, Business administration, Marketing, Wall Street, Watson Labs, Villalba v Merrill Lynch & Co Inc, Sclerosis, Heart failure, Intercept Pharmaceuticals, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

Key Points: 
  • Mr. Cullen brings Lexicon more than 35 years of industry experience in market access and sales leadership.
  • Before joining Lexicon, Matt served as vice president, value, access and policy at Apellis Pharmaceuticals where he led the market access launch of rare disease drug EMPAVELI® (pegcetacoplan) and ophthalmology drug SYFOVRE® (pegcetacoplan injection).
  • His responsibilities included pricing and contracting, payer strategy and marketing, corporate and strategic account management, field reimbursement, trade and distribution, and training.
  • Prior to Apellis, Mr. Cullen led strategic payer marketing and access teams at Bristol-Myers Squibb for ELIQUIS® (apixaban) and ORENCIA® (abatacept).